If it works in neurons, this disposal pathway could have implications for neurodegenerative disease.
Quality control issues may have scuppered clinical trials.
NIH funds a five-year project to validate biomarkers for clinical trials.
ALS patients eliminate more p75 neurotrophin receptor than do healthy controls. P75 urine levels rise as disease worsens.
Going from normal zzzs to sleeping longer than nine hours a night more than doubles a person’s risk of developing dementia, study says.
In AD mouse brain, transplanted human neurons develop more tau pathology and die more readily than neighboring mouse neurons.
Produced by the dreaded MRSA bacterium, PSMα3 is the first known example of a natural peptide that forms amyloid fibers made not of β-sheets, but of neatly stacked α-helices.
A well-controlled trials shows that a year of treatment offers no cognitive benefit for older men with low testosterone levels.
The extracellular fragment of TREM2, but not of its AD variants, promotes microglial survival, activation. To do that, it does not need the full-length TREM2 receptor.
Growing expansions in the C9ORF72 gene may lead to earlier onset of amyotrophic lateral sclerosis and/or frontotemporal dementia symptoms with each passing generation.
Thousands of hits on the ol’ noggin during a soccer player’s career might lead to concussive symptoms and, eventually, dementia.
The EPOCH trial of verubecestat was halted for lack of efficacy. APECS trial in prodromal AD continues.
In cell cultures, excess cytoplasmic TDP-43 shut down global translation and triggered formation of protein inclusions.
Transgenic mouse models devoid of gut microbes make fewer Aβ plaques.
Using yeast as springboard, researchers deploy a new computational tool to trace the biology driving α-synuclein pathology in people. The hope: to find pathways that will inform future therapies.